NCT03079531View on ClinicalTrials.gov

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

January 25, 2019

Study Completion Date

January 25, 2019

Conditions
Papulopustular Rosacea
Interventions
DRUG

Secukinumab

Secukinumab 300 mg administered subcutaneously.

Trial Locations (1)

94603

Stanford Dermatology, Redwood City

All Listed Sponsors
lead

Anne Chang

OTHER

NCT03079531 - Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea | Biotech Hunter | Biotech Hunter